UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting
UNITY Biotechnology (NASDAQ: UBX) announced the presentation of 24-week clinical data from its Phase 1 study of UBX1325 at the ASRS 40th Annual Scientific Meeting, scheduled for July 14, 2022. UBX1325 is being developed for treating diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The investigational therapy has shown a favorable safety profile and improvements in visual acuity. The company aims to offer transformative outcomes for patients suffering from age-related ocular diseases.
- UBX1325 demonstrated a favorable safety profile in advanced vascular eye disease.
- Improvements in visual acuity were sustained through 24 weeks after a single dose.
- None.
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting 2022, being held July 13-16, 2022. Details of the presentations are as follows:
Title: UBX1325, A Novel Senolytic Therapy for Treatment Experienced Patients With Chronic DME or Wet AMD: 24-Week Results of a Phase 1 Study
Session: Wet AMD 1 Symposium
Date & Time: Thursday, July 14 at 8:15 a.m. ET
Speaker: Raj Maturi, M.D., Midwest Eye Institute, Department of Ophthalmology, Indiana University School of Medicine
About UBX1325
UBX1325 is an investigational compound being studied for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR) that is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. In a Phase 1 clinical study in advanced vascular eye disease, UBX1325 has shown a favorable safety profile and improvements in visual acuity sustained through 24 weeks following a single dose. In preclinical studies, UNITY has demonstrated that targeting Bcl-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, AMD, and DR.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, our expectations regarding potential benefits, activity, effectiveness, and safety of UBX1325, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of results of our studies of UBX1325, the timing of the expected commencement, progression, and conclusion of our studies including those of UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITY’s most recently filed Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 15, 2022, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Media Contact
Canale Communications
Jason Spark
Jason.spark@evokegroup.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
What are the results of the Phase 1 study of UBX1325?
When will the clinical data for UBX1325 be presented?
What is UBX1325 and its purpose?
What does the favorable safety profile of UBX1325 imply?
